The 5th China International Import Expo (CIIE) saw the Bo’ao Lecheng Medical Tourism Pilot Zone management bureau announce a series of strategic partnerships with multinational companies. These collaborations aim to enhance the zone’s capabilities in medical tourism and healthcare innovation.
Partnership with Abbott Laboratories
Boao Yiling and Abbott Laboratories’ diabetes department partnered to improve the convenience and accessibility of diabetes management solutions. The collaboration leverages policy and platform advantages in Lecheng to enhance patient outcomes and streamline diabetes care.
Partnership with Gilead Sciences
The Lecheng bureau agreed with Gilead Sciences to accelerate the implementation of clinically urgent products and diagnosis and treatment plans. The partnership also supports the normalization of real-world data-based research and application, further solidifying Lecheng’s role in advancing healthcare solutions.
Partnership with Takeda China
Lecheng also signed a deal with Takeda China regarding its teduglutide, a therapy for short bowel syndrome expected to enter the pilot zone. This collaboration aims to facilitate clinical testing and gather real-world data to support regulatory filings.
Partnership with Lumenis
In addition, Lecheng teamed up with Israel-based medical laser firm Lumenis to allow clinical testing and gathering of real-world data to support an approval filing. This partnership underscores Lecheng’s commitment to integrating advanced medical technologies and expanding its healthcare offerings.
Deepening Partnership with Allergan Aesthetics
Lecheng further deepened its partnership with Allergan Aesthetics, an AbbVie company, to enhance clinical research related to novel drugs and medical devices. The collaboration includes support for new product commercialization, clinical application training, promotion, and international exchanges and cooperation, positioning Lecheng as a hub for medical innovation.-Fineline Info & Tech
